Active Ingredient(s): Atogepant
FDA Approved: * September 28, 2021
Pharm Company: * ABBVIE INC
Category: Migraine / Tension Headache

Atogepant, sold under the brand name Qulipta, is a medication used to treat migraines. It is a gepant, an orally active calcitonin gene-related peptide receptor (CGRPR) antagonist.[1][2] It was approved for medical use in the United States in September 2021.[1][3] References .mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Qulipta 60 mg Oral Tablet
NDC: 0074-7094
Abbvie Inc.
Qulipta 10 mg Oral Tablet
NDC: 0074-7095
Abbvie Inc.
Qulipta 30 mg Oral Tablet
NDC: 0074-7096
Abbvie Inc.